Paul Weller
Bankstown Lidcombe Hospital(AU)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, Melanoma and MAPK Pathways, Drug Transport and Resistance Mechanisms, Synthesis and biological activity, Computational Drug Discovery Methods
Most-Cited Works
- → Quantitative studies of hydroperoxide reduction by prostaglandin H synthase. Reducing substrate specificity and the relationship of peroxidase to cyclooxygenase activities.(1987)217 cited
- → Unbound Drug Concentration in Brain Homogenate and Cerebral Spinal Fluid at Steady State as a Surrogate for Unbound Concentration in Brain Interstitial Fluid(2008)178 cited
- → Design and Synthesis of 4-Azaindoles as Inhibitors of p38 MAP Kinase(2003)95 cited
- → In silico and in vitro pharmacogenetics: aldehyde oxidase rapidly metabolizes a p38 kinase inhibitor(2010)86 cited
- → Reaction of malondialdehyde with guanine nucleosides: formation of adducts containing oxadiazabicyclononene residues in the base-pairing region(1986)76 cited
- → Enhanced delayed matching performance in younger and older macaques administered the 5-HT 4 receptor agonist, RS 17017(1998)75 cited
- → Discovery of 6-(2,4-Difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Pamapimod) and 6-(2,4-Difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as Orally Bioavailable and Highly Selective Inhibitors of p38α Mitogen-Activated Protein Kinase(2011)74 cited
- → In silico pharmacogenetics of warfarin metabolism(2006)65 cited
- → Discovery of S-[5-Amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an Orally Bioavailable and Highly Selective Inhibitor of p38 Map Kinase(2006)64 cited
- → Rational design of 6-methylsulfonylindoles as selective cyclooxygenase-2 inhibitors(2004)59 cited